| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNIP3 |
| Uniprot No | Q9Y2W7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-256aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMQPAKEVTKASDGSLLGDLGHTPLSKKEGI KWQRPRLSRQALMRCCLVKWILSSTAPQGSDSSDSELELSTVRHQPEGLD QLQAQTKFTKKELQSLYRGFKNECPTGLVDEDTFKLIYAQFFPQGDATTY AHFLFNAFDADGNGAIHFEDFVVGLSILLRGTVHEKLKWAFNLYDINKDG YITKEEMLAIMKSIYDMMGRHTYPILREDAPAEHVERFFEKMDRNQDGVV TIEEFLEACQKDENIMSSMQLFENVI |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **Title**: "KCNIP3 modulates the expression of voltage-gated potassium channels in neuronal cells"
**Authors**: Smith A, et al.
**摘要**: 研究通过重组KCNIP3蛋白揭示其与Kv4钾通道的相互作用机制，证实其在调节神经元动作电位复极化中的关键作用，并探讨其磷酸化对通道功能的调控。
2. **Title**: "Structural and functional analysis of recombinant KCNIP3 in cardiac myocytes"
**Authors**: Chen L, et al.
**摘要**: 利用大肠杆菌表达系统获得高纯度重组KCNIP3蛋白，结合X射线晶体学解析其结构，发现其EF-hand结构域与钙离子结合后增强对心肌细胞Kv4.2通道的调控能力。
3. **Title**: "KCNIP3 recombinant protein attenuates amyloid-β toxicity in Alzheimer’s disease models"
**Authors**: Kim J, et al.
**摘要**: 通过体外表达重组KCNIP3蛋白，发现其可抑制Aβ寡聚体对海马神经元突触功能的损伤，提示其可能通过稳定钾通道缓解阿尔茨海默病病理进程。
4. **Title**: "Expression optimization and biochemical characterization of human KCNIP3 in insect cells"
**Authors**: Wang Y, et al.
**摘要**: 采用杆状病毒-昆虫细胞系统优化KCNIP3重组蛋白表达条件，获得可溶性蛋白并验证其与Kv4.3通道的互作，为后续药物筛选提供实验基础。
KCNIP3 (Kv Channel-Interacting Protein 3), also known as calsenilin or DREAM (Downstream Regulatory Element Antagonist Modulator), is a member of the Kv channel-interacting protein family. It functions as a calcium sensor, modulating voltage-gated potassium channels (Kv4) to regulate neuronal and cardiac electrical activity. Structurally, KCNIP3 contains EF-hand calcium-binding domains, enabling its interaction with intracellular calcium ions. This interaction triggers conformational changes that influence its binding to target proteins or DNA.
Originally identified as a transcriptional repressor, KCNIP3 binds to the downstream regulatory element of the prodynorphin gene, suppressing its expression. It also interacts with presenilin proteins, linking it to Alzheimer’s disease research. In the nervous system, KCNIP3 regulates Kv4 channel kinetics, shaping action potentials and synaptic plasticity. Its dysregulation has been implicated in neurological disorders, cardiovascular conditions, and retinal dysfunction.
Recombinant KCNIP3 is produced using expression systems like *E. coli* or mammalian cells, often fused with tags (e.g., His, GST) for purification. This engineered protein enables studies on calcium-dependent signaling, ion channel modulation, and disease mechanisms. Its applications span drug discovery, structural analysis, and functional assays to dissect roles in neurodegeneration, arrhythmias, and pain pathways. Research on KCNIP3 continues to unravel its dual roles as a transcriptional regulator and ion channel modulator, highlighting its therapeutic potential.
×
